Pharmaceutical care on a pulmonary thromboembolism patient with thrombocytopenia induced by low molecular heparin
LIANG Jin-mei
ZHU Man
CHEN Meng-li
HU Jing
CHAI Dong
Abstract：To summarize the key points of pharmaceutical care on a pulmonary thromboembolism patient with heparin-induced thrombocytopenia (HIT). Literature concerning HIT published in domestic and international journals were reviewed. The ADR relevance of the example was evaluated, and the treatment progress of anticoagulant drugs was summarized, which could guide the selection and usage of anticoagulant drugs in clinic. According to the relevance evaluation criterion formulated by national ADR monitoring center, the relevance evaluation results was possible, while the result was highly possible evaluated by 4T's scoring system. Heparin should be discontinued (including heparin lfushing) when HIT occurred, and non-heparin anticoagulant drugs could be used, such as argatroban, danaparoid, bivalirudin, fondaparinux sodium and new oral anticoagulants. Warfarin is the contraindication in the treatment of acute HIT, which can lead to limb vein necrosis, and warfarin could be reused when the platelet count recovered (150×109·L-1).
Keywords：Low molecular heparinThrombocytopeniaPharmaceutical carePulmonary thromboembolismFondaparinux sodiumAnticoagulant
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 157-159 )